In NSCLC, the majority of all EGFR mutations are EGFRL858R in exon 21 and activating EGFR exon 19 deletions, and tumor cells harboring the specific activating mutations exhibit high sensitivity to EGFR–TKIs.175, 176. Here, EGFR is linked to neoplasm.